Leerink Partnrs Brokers Lower Earnings Estimates for MAZE
Maze Therapeutics, Inc. (NASDAQ:MAZE – Free Report) – Research analysts at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for shares of Maze Therapeutics in a research report issued to clients and investors on Monday, March 31st. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.64) […]
Maze Therapeutics, Inc. (NASDAQ:MAZE – Free Report) – Research analysts at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for shares of Maze Therapeutics in a research report issued to clients and investors on Monday, March 31st. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.64) […]